GNI Group to acquire Ayumi Pharmaceutical in ¥44.8bn deal
GNI Group has agreed to acquire 100% of Ayumi Pharmaceutical Holdings from a shareholder group led by Blackstone in a deal that values the Japanese specialty pharma company at approximately ¥44.8 billion (roughly $300 million at current rates). The transaction, announced on 7 June 2026, will make Ayumi a wholly owned subsidiary of GNI Group and represents one of the more substantial inbound consolidation moves in Japan's pharmaceutical market this year.
Ayumi is best known for Calonal, a branded acetaminophen product that the company says holds more than 80% of Japan's domestic acetaminophen market. Beyond pain management, Ayumi maintains a portfolio serving rheumatology and orthopaedic patients and operates a nationwide commercial network reaching hospitals and clinics across Japan. For the fiscal year ended March 2026, the company reported revenue of approximately ¥38.5 billion and operating profit of approximately ¥6.2 billion.
The deal
GNI Group is projecting combined fiscal 2026 revenue of approximately ¥65.2 billion following the close of the transaction, implying a meaningful step-up from its current standalone base. The combined organisation will focus on five therapeutic areas: fibrosis, pain management, rheumatology, oncology, and orthopaedics.
Ying Luo, President and Chief Executive of GNI Group, described the deal as "a monumental milestone" in establishing the company as a "cross-Pacific biopharmaceutical powerhouse," citing Ayumi's domestic commercial infrastructure as a channel through which GNI intends to introduce biosimilars and in-house pipeline assets into Japan. Atsuhiko Sakamoto, Head of Private Equity at Blackstone Japan, noted that Ayumi was Blackstone's first control private equity investment in Japan and said the firm had helped build the company's market leadership before exiting to GNI.
As part of the deal, Blackstone, Toho, and Hisamitsu will become shareholders in the enlarged GNI Group, indicating that a portion of the consideration is being taken in equity rather than entirely in cash — though GNI did not break down the payment structure in its announcement.
Market context
Japan's pharmaceutical market sits among the world's three largest by value, yet it has historically been difficult territory for foreign-domiciled groups to penetrate without a local commercial partner or acquisition. GNI Group — headquartered in Tokyo but with operations spanning China, the United States, and Australia — is positioning the Ayumi deal as its primary mechanism for scaling domestic distribution rather than building from scratch.
The transaction fits a broader pattern of mid-sized cross-border pharmaceutical consolidation in Asia Pacific, where acquirers are seeking recurring-revenue commercial platforms to de-risk earlier-stage pipeline assets. Ayumi's entrenched position in acetaminophen and rheumatology gives GNI a stable cash-generative base, though the strategic value will ultimately depend on the company's ability to leverage Ayumi's hospital relationships to commercialise differentiated products — including biosimilars, where Japan's uptake has lagged European markets despite regulatory reforms in recent years.
Investors will watch for clarity on the financing structure, a timeline to close, and any indication of how GNI intends to integrate Ayumi's contract manufacturing operations, which represent a distinct business line not prominently featured in the strategic rationale.